My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 221

    1.

    Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.

    Kuhlmann J, Neumann-Haefelin C, Belz U, Kalisch J, Juretschke HP, Stein M, Kleinschmidt E, Kramer W, Herling AW.

    Diabetes. 2003 Jan;52(1):138-44.PMID: 12502504 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.

    Jucker BM, Schaeffer TR, Haimbach RE, Mayer ME, Ohlstein DH, Smith SA, Cobitz AR, Sarkar SK.

    Metabolism. 2003 Feb;52(2):218-25.PMID: 12601636 [PubMed - indexed for MEDLINE]Related articles

    3.

    Proton magnetic resonance spectroscopy study of soleus muscle in non-obese healthy and Type 2 diabetic Asian Northern Indian males: high intramyocellular lipid content correlates with excess body fat and abdominal obesity.

    Misra A, Sinha S, Kumar M, Jagannathan NR, Pandey RM.

    Diabet Med. 2003 May;20(5):361-7.PMID: 12752484 [PubMed - indexed for MEDLINE]Related articles

    4.

    Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity.

    Sinha R, Dufour S, Petersen KF, LeBon V, Enoksson S, Ma YZ, Savoye M, Rothman DL, Shulman GI, Caprio S.

    Diabetes. 2002 Apr;51(4):1022-7.PMID: 11916921 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects.

    Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Häring HU.

    Diabetes. 1999 May;48(5):1113-9.PMID: 10331418 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Relationship between visceral adiposity and intramyocellular lipid content in two rat models of insulin resistance.

    Korach-André M, Gao J, Gounarides JS, Deacon R, Islam A, Laurent D.

    Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E106-16. Epub 2004 Aug 24.PMID: 15328072 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects.

    Schrauwen-Hinderling VB, Kooi ME, Hesselink MK, Jeneson JA, Backes WH, van Echteld CJ, van Engelshoven JM, Mensink M, Schrauwen P.

    Diabetologia. 2007 Jan;50(1):113-20. Epub 2006 Nov 9.PMID: 17093944 [PubMed - indexed for MEDLINE]Related articles

    8.

    Age and muscle-type modulated role of intramyocellular lipids in the progression of insulin resistance in nondiabetic Zucker rats.

    Korach-André M, Gounarides J, Deacon R, Beil M, Sun D, Gao J, Laurent D.

    Metabolism. 2005 Apr;54(4):522-8.PMID: 15798961 [PubMed - indexed for MEDLINE]Related articles

    9.

    Determinants of intramyocellular lipid concentrations in rat hindleg muscle.

    Neumann-Haefelin C, Kuhlmann J, Belz U, Kalisch J, Quint M, Gerl M, Juretschke HP, Herling AW.

    Magn Reson Med. 2003 Aug;50(2):242-8.PMID: 12876699 [PubMed - indexed for MEDLINE]Related articles

    10.

    Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.

    Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM.

    Metabolism. 2001 Nov;50(11):1294-300.PMID: 11699047 [PubMed - indexed for MEDLINE]Related articles

    11.

    Increased intramyocellular lipid content but normal skeletal muscle mitochondrial oxidative capacity throughout the pathogenesis of type 2 diabetes.

    De Feyter HM, Lenaers E, Houten SM, Schrauwen P, Hesselink MK, Wanders RJ, Nicolay K, Prompers JJ.

    FASEB J. 2008 Nov;22(11):3947-55. Epub 2008 Jul 24.PMID: 18653763 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats.

    Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD.

    Diabetes. 2001 Jan;50(1):123-30.PMID: 11147777 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents.

    Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L.

    Diabetes. 1999 Aug;48(8):1600-6.PMID: 10426379 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Muscle type-specific fatty acid metabolism in insulin resistance: an integrated in vivo study in Zucker diabetic fatty rats.

    Beha A, Juretschke HP, Kuhlmann J, Neumann-Haefelin C, Belz U, Gerl M, Kramer W, Roden M, Herling AW.

    Am J Physiol Endocrinol Metab. 2006 May;290(5):E989-97. Epub 2005 Dec 27.PMID: 16380389 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study.

    Jucker BM, Schaeffer TR, Haimbach RE, McIntosh TS, Chun D, Mayer M, Ohlstein DH, Davis HM, Smith SA, Cobitz AR, Sarkar SK.

    Diabetes. 2002 Jul;51(7):2066-73.PMID: 12086934 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.

    Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.

    Metabolism. 2007 Oct;56(10):1418-24.PMID: 17884455 [PubMed - indexed for MEDLINE]Related articles

    17.

    The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

    Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF.

    Diabetes. 2002 Mar;51(3):797-802.PMID: 11872682 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats.

    Maier VH, Melvin DR, Lister CA, Chapman H, Gould GW, Murphy GJ.

    Diabetes. 2000 Apr;49(4):618-25.PMID: 10871200 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Metabolic implications of dietary trans-fatty acids.

    Dorfman SE, Laurent D, Gounarides JS, Li X, Mullarkey TL, Rocheford EC, Sari-Sarraf F, Hirsch EA, Hughes TE, Commerford SR.

    Obesity (Silver Spring). 2009 Jun;17(6):1200-7. Epub 2009 Feb 19. Erratum in: Obesity (Silver Spring). 2009 Jul;17(7):1474. PMID: 19584878 [PubMed - indexed for MEDLINE]Related articles

    20.

    Adipocyte differentiation-related protein and OXPAT in rat and human skeletal muscle: involvement in lipid accumulation and type 2 diabetes mellitus.

    Minnaard R, Schrauwen P, Schaart G, Jorgensen JA, Lenaers E, Mensink M, Hesselink MK.

    J Clin Endocrinol Metab. 2009 Oct;94(10):4077-85. Epub 2009 Jul 14.PMID: 19602560 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity